Connection
Jennifer Diamond to Receptors, Estrogen
This is a "connection" page, showing publications Jennifer Diamond has written about Receptors, Estrogen.
|
|
Connection Strength |
|
 |
|
 |
|
0.716 |
|
|
|
-
Owsley J, Jimeno A, Diamond JR. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer. Drugs Today (Barc). 2016 Feb; 52(2):119-29.
Score: 0.431
-
Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3329-3338.
Score: 0.154
-
Weiss J, Afghahi A, Shagisultanova E, Diamond JR. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer. Oncology (Williston Park). 2018 Oct 15; 32(10):513-5.
Score: 0.130
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|